Morphologic Types of Tricuspid Regurgitation Characteristics and Prognostic Implications

Total Page:16

File Type:pdf, Size:1020Kb

Morphologic Types of Tricuspid Regurgitation Characteristics and Prognostic Implications JACC: CARDIOVASCULAR IMAGING VOL. 12, NO. 3, 2019 ª 2019 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER STATE-OF-THE-ART PAPER Morphologic Types of Tricuspid Regurgitation Characteristics and Prognostic Implications a,b a c d Edgard A. Prihadi, MD, Victoria Delgado, MD, PHD, Martin B. Leon, MD, PHD, Maurice Enriquez-Sarano, MD, PHD, e a Yan Topilsky, MD, PHD, Jeroen J. Bax, MD, PHD ABSTRACT Tricuspid regurgitation (TR) is classified according to different morphologic types based on the underlying mechanisms: primary, secondary, and isolated TR. Primary TR is caused by an anatomical abnormality of the tricuspid valve apparatus. Secondary TR is caused by dilation of the tricuspid valve annulus, related to right ventricular (RV), or right atrial remodeling and increased RV pressures (often secondary to left-sided heart disease). Isolated TR can exist in patients without increased RV pressures and is frequently associated with atrial fibrillation. Two-dimensional echocardiography plays a pivotal role in the assessment of the etiology and severity of TR. Views from 3-dimensional techniques have significantly increased the understanding of the pathophysiology of each morphologic type of TR (leaflet damage, annular dilation, and distinct patterns of right-heart remodeling). The following review will describe the etiology, anatomical and functional characteristics, and outcomes of each morphologic type of TR, and furthermore addresses challenging pitfalls in the referral for tricuspid valve intervention. (J Am Coll Cardiol Img 2019;12:491–9) © 2019 by the American College of Cardiology Foundation. uring the last 2 decades, insights into the morphologic types of TR can be distinguished, D natural history and pathophysiology of depending on the presence of a primary abnormality tricuspid regurgitation (TR) have shifted of the TV apparatus (primary TR), dilation of the TV the treatment of TR from a conservative approach, annulus, leaflet tethering, and right ventricular (RV) to an approach of intervention and potential remodeling (due to left-sided heart disease and prevention. Advances in echocardiographic tech- pulmonary hypertension) (secondary TR) or atrial niques and the development of 3-dimensional (3D) fibrillation (AF) and right atrial (RA) remodeling imaging modalities have further allowed more accu- (isolated TR) (Central Illustration). Along with growing rate assessment of tricuspid valve (TV) morphology, insights into the deleterious outcomes of untreated mechanisms of TR, severity of TR, and more detailed TR and high mortality risk associated with surgical evaluation of the extent of right-heart remodeling, all intervention, novel transcatheter devices have been potentially contributing to TR progression. Different developed. This review will describe the different From the aDepartment of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; bDepartment of Cardiology, ZNA Middelheim Hospital, Antwerpen, Belgium; cDepartment of Cardiology, Columbia University Medical Center, New York, New York; dCardiovascular Diseases Division, Mayo Clinic, Rochester, Minnesota; and the eDepartment of Cardiology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv, Israel. The Department of Cardiology of the Leiden University Medical Center has received research grants from Boston Scientific, Medtronic, Biotronik, Edwards Lifesciences, and GE Healthcare. Dr. Delgado has received personal fees from Abbott Vascular. Dr. Enriquez-Sarano has received grants from Edwards LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Manuscript received June 18, 2018; revised manuscript received September 17, 2018, accepted September 20, 2018. ISSN 1936-878X/$36.00 https://doi.org/10.1016/j.jcmg.2018.09.027 492 Prihadi et al. JACC: CARDIOVASCULAR IMAGING, VOL. 12, NO. 3, 2019 TR Phenotype and Prognosis MARCH 2019:491– 9 ABBREVIATIONS types of TR and their anatomical and reduced left ventricular (LV) ejection fraction pre- AND ACRONYMS functional characteristics and outcomes. senting with acute (19) or chronic (20–22) heart failure Furthermore, pitfalls in the preprocedural (HF), significant TR is commonly observed which can AF = atrial fibrillation risk stratification will be addressed. progress further despite optimal medical therapy and CI = confidence interval cardiac resynchronization therapy (Figure 1) (23). EROA TYPES OF TR: PRIMARY, SECONDARY, = effective regurgitant Pulmonary hypertension, arising from other causes orifice area AND ISOLATED than left-sided heart disease, includes primary pul- HF = heart failure monary hypertension, pulmonary embolism, and HR = hazard ratio TR is a relatively common valvular heart chronic pulmonary disease. These etiologies can LV disease which is classified based on the = left ventricular cause TR due to increased RV afterload, RV dilation, underlying mechanism as primary or sec- RV = right ventricular anddysfunction.Furthermore,intheabsenceof ondary. The estimated frequency of primary TR = tricuspid regurgitation pulmonary hypertension, diseases directly affecting TR is 8% to 10%, less frequent than second- TV = tricuspid valve the RV function such as ischemia in inferior myocar- ary TR which accounts for the most frequent dial infarction (24,25) or arrhythmogenic mechanism of TR. RV dysplasia/cardiomyopathy (26) can lead to TR Primary TR is caused by an abnormality of any of through apical displacement of the papillary muscles the components of the TV apparatus (tricuspid leaf- and increased tethering of the TV leaflets. lets, chordae, papillary muscles, or annulus), due to Finally, other than primary or secondary TR, congenital or acquired causes. The most common isolated TR is a morphologic type of TR which is congenital abnormality of the TV is Ebstein’sdisease increasingly recognized as a separate entity. In the characterized by an apical displacement of the leaflets absence of concomitant pulmonary hypertension or which arise directly from the wall of the RV without co-existing left-sided heart disease, isolated TR is identifiable chordae (1). Acquired causes of primary mainly present in elderly patients with a high prev- TR include tumors (such as carcinoid disease and alence of AF causing RA dilation, TV annulus dilation, myxoma), iatrogenic injury (such as RV endomyo- and TV leaflets malcoaptation (Figure 1) (27–29). cardial biopsy, transvenous pacing, or defibrillator leads), drug-induced leaflet damage (such as HOW TO ASSESS THE ANATOMICAL AND anorectic drugs, dopamine agonists, and ergot FUNCTIONAL CHARACTERISTICS OF alkaloids) (2), systemic diseases (such as lupus VARIOUS TYPES OF TR erythematosus and sarcoidosis), radiation, rheumatic disease, endocarditis, and trauma (3).Amongac- Table 1 summarizes the different echocardiographic quired causes of TR, transvenous pacemaker or defi- characteristics of primary,secondary,andisolated brillator lead-induced TR is one of the most frequent TR. In primary TR, echocardiographic assessment of etiologies. With aging of the global population and individual leaflet pathology by 2-dimensional (2D) an increasing number of patients with pacemaker echocardiography is particularly challenging because devices, the prevalence of lead-induced TR may of anatomic variability in size and number of leaflets increase considerably. Among patients without TR and only 2 TV leaflets can be visualized simulta- before pacemaker implantation, up to 38% may neously on routine echocardiographic views. 3D develop significant TR over the following 1 to echocardiographic imaging permits more accurate 1.5 years after lead insertion (Figure 1) (4). individual leaflet identification by providing the “en SecondaryTRisfrequentlycausedbyRVdilation face” visualization of the TV, further improving and dysfunction, leading to leaflet tethering, assessment of leaflet morphology and mobility and tricuspid annulus dilation, and malcoaptation (5).The involvement of the subvalvular apparatus (30,31). most frequent causes of secondary TR include co- Whereas myxomatous valve disease is characterized existing left-sided valvular and myocardial disease by the presence of redundant tissue with excess associated with increased left atrial pressures, pul- leaflet mobility (32), thickened leaflets with a monary hypertension, and increased RV afterload. restrictive motion can be caused by carcinoid syn- Thirty percent to 50% of patients with severe mitral drome (33) or less frequently rheumatic involvement. regurgitation (6) and more than 25% of patients with Lead-induced TR can be caused by impingement severe aortic stenosis (7) show significant (moderate of the tricuspid leaflet by the lead itself, leaflet and severe) TR. Furthermore, after surgical or trans- perforation, laceration or avulsion, and transection catheter treatment of mitral regurgitation (8–13) or of papillary muscles or chordae tendineae (34,35). aortic stenosis (14–18), progression or late onset of TR In TR after pacemaker/defibrillator-lead implanta- can frequently occur. Similarly, in patients with tion, diagnosing the cause of TR remains challenging JACC: CARDIOVASCULAR IMAGING, VOL. 12, NO. 3, 2019 Prihadi et al. 493 MARCH 2019:491– 9 TR Phenotype and Prognosis CENTRAL ILLUSTRATION Schematic Drawing of the Different Morphologic Types of Tricuspid Regurgitation Prihadi, E.A. et al. J Am Coll Cardiol Img. 2019;12(3):491–9. Primary tricuspid regurgitation (A), where there is primary damage of the tricuspid valve apparatus (prolapse of the posterior
Recommended publications
  • Ischemic Cardiomyopathy: Symptoms, Causes, & Treatment
    Ischemic Cardiomyopathy Ischemic cardiomyopathy is a condition that occurs when the heart muscle is weakened due to insufficient blood flow to the heart's muscle. This inhibits the heart's ability to pump blood and can lead to heart failure. What Is Ischemic Cardiomyopathy? Ischemic cardiomyopathy (IC) is a condition that occurs when the heart muscle is weakened. In this condition, the left ventricle, which is the main heart muscle, is usually enlarged and dilated. This condition can be a result of a heart attack or coronary artery disease, a narrowing of the arteries. These narrowed arteries keep blood from reaching portions of your heart. The weakened heart muscle inhibits your heart’s ability to pump blood and can lead to heart failure. Symptoms of IC include shortness of breath, chest pain, and extreme fatigue. If you have IC symptoms, you should seek medical care immediately. Treatment depends on how much damage has been done to your heart. Medications and surgery are often required. You can improve your long-term outlook by making certain lifestyle changes, such as maintaining a healthy diet and avoiding high-risk behaviors, including smoking. Symptoms of Ischemic Cardiomyopathy You can have early-stage heart disease with no symptoms. As the arteries narrow further and blood flow becomes impaired, you may experience a variety of symptoms, including: shortness of breath extreme fatigue dizziness, lightheadedness, or fainting chest pain and pressure (angina) heart palpitations weight gain swelling in the legs and feet (edema) and abdomen difficulty sleeping cough or congestion caused by fluid in the lungs If you have these symptoms, seek emergency medical care or call 9-1-1.
    [Show full text]
  • ICD-10-CM Documentation and Coding Best Practices
    ICD-10-CM Documentation and Coding Best Practices Cardiomyopathy Cardiomyopathy refers to diseases of the heart muscle, which can become enlarged, thick or rigid. In rare cases, cardiac muscle tissue can be replaced with scar tissue. As the condition worsens, the heart becomes weaker and less able to pump blood through the body or to maintain a normal electrical rhythm. Causes Risk factors that can increase the possibility of developing cardiomyopathy include: coronary artery disease, a history of heart attack (s), viral infections that cause heart inflammation, long-term hypertension or alcoholism, obesity, and diabetes to name a few. However, in most cases the exact cause is usually unknown (called primary or idiopathic cardiomyopathy). Symptoms Some patients will never have symptoms; others will not develop them until later in the disease. Symptoms can include: • Fatigue • Shortness of b reath or trouble breathing (dyspnea) • Dizziness, lightheadedness or fainting • Swelling in the ankles, feet, legs, abdomen and neck veins Treatment Treatment depends on the type of cardiomyopathy, the severity of symptoms, and the patient’s age and overall health. • Lifestyle changes can help manage condition(s) that may be causing cardiomyopathy. Recommendations include: o Consuming a heart healthy diet, engaging in physical activity, losing excess weight, giving up smoking, avoiding alcohol and illegal drugs, getting enough sleep, and reducing stress • Medicines may be p rescribed to: o Lower blood pressure (ACE inhibitors, angiotensin II receptor blo ckers, beta blockers, calcium channel blockers ) o Slow the heart rate (beta blockers, calcium channel blockers, digoxin) o Prevent arrhythmias (antiarrhythmics) o Remove excess fluid and sodium (diuretics) o Prevent blood clots (anticoagulants) • Alcohol septal ablation • Surgery o Septal myectomy – option for severe cases of obstructive hypertrophic cardiomyopathy Surgically implanted devices o .
    [Show full text]
  • Ischemic Mitral Regurgitation: a Multifaceted Syndrome with Evolving Therapies
    biomedicines Review Ischemic Mitral Regurgitation: A Multifaceted Syndrome with Evolving Therapies Mattia Vinciguerra 1,* , Francesco Grigioni 2, Silvia Romiti 1 , Giovanni Benfari 3,4, David Rose 5 , Cristiano Spadaccio 5,6, Sara Cimino 1, Antonio De Bellis 7 and Ernesto Greco 1 1 Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy; [email protected] (S.R.); [email protected] (S.C.); [email protected] (E.G.) 2 Unit of Cardiovascular Sciences, Department of Medicine Campus Bio-Medico, University of Rome, 00128 Rome, Italy; [email protected] 3 Division of Cardiology, Department of Medicine, University of Verona, 37219 Verona, Italy; [email protected] 4 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA 5 Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool FY3 8NP, UK; [email protected] (D.R.); [email protected] (C.S.) 6 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, UK 7 Department of Cardiology and Cardiac Surgery, Casa di Cura “S. Michele”, 81024 Maddaloni, Caserta, Italy; [email protected] * Correspondence: [email protected] Abstract: Dysfunction of the left ventricle (LV) with impaired contractility following chronic ischemia or acute myocardial infarction (AMI) is the main cause of ischemic mitral regurgitation (IMR), leading to moderate and moderate-to-severe mitral regurgitation (MR). The site of AMI exerts a specific Citation: Vinciguerra, M.; Grigioni, influence determining different patterns of adverse LV remodeling. In general, inferior-posterior F.; Romiti, S.; Benfari, G.; Rose, D.; AMI is more frequently associated with regional structural changes than the anterolateral one, which Spadaccio, C.; Cimino, S.; De Bellis, is associated with global adverse LV remodeling, ultimately leading to different phenotypes of IMR.
    [Show full text]
  • Ischemic Cardiomyopathy: Contemporary Clinical Management
    Chapter 7 Ischemic Cardiomyopathy: Contemporary Clinical Management BurhanBurhan Sheikh Alkar, Sheikh Alkar, Gustav MattssonGustav Mattsson and PeterPeter Magnusson Magnusson Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.76723 Abstract Ischemic cardiomyopathy, disease of the heart muscle due to coronary artery disease, is the most common cardiomyopathy. It is often difficult to discern the etiology of heart failure, and often there are multiple underlying causes. Ischemic cardiomyopathy most often pres - ents with a dilated morphology with wall motion defects and a history of previous myocar - dial infarction or confirmed coronary artery disease. Mechanisms of myocardial depression in ischemia are necrosis of myocardial cells resulting in irreversible loss of function or reversible damage, either short term through myocardial stunning or long term through hibernation. In ischemic cardiomyopathy, echocardiography may be extended with stress testing or other imaging modalities such as myocardial scintigraphy and cardiac magnetic resonance tomography. Coronary angiography is often considered a gold standard; how - ever, other modalities such as positron emission tomography can be needed to detect small vessel disease. Cardiac revascularization, through percutaneous coronary intervention and coronary artery bypass grafting, both in acute coronary syndrome and in stable coronary artery disease, relieves symptoms and improves prognosis. Therapy should aspire to treat ischemia, arrhythmias in addition to heart failure management, which includes device therapy with cardiac resynchronization therapy, implantable cardioverter defibrillators, and mechanical support as bridging or destination therapy in end-stage disease. Keywords: cardiomyopathy, coronary artery disease, heart failure, ischemic, myocardial infarction 1. Introduction Disease of the heart muscle, cardiomyopathy, appears in various disease manifestations, which are often either poorly defined or difficult to distinguish in clinical practice.
    [Show full text]
  • Decompensated Non-Ischemic Cardiomyopathy Induced by Anabolic-Androgenic Steroid Abuse
    Open Access Case Report DOI: 10.7759/cureus.11476 Decompensated Non-Ischemic Cardiomyopathy Induced by Anabolic-Androgenic Steroid Abuse Palwinder Sodhi 1 , Meera R. Patel 1 , Anup Solsi 2 , Pallavi Bellamkonda 3 1. Cardiology, Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, USA 2. Internal Medicine, Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, USA 3. Cardiovascular Disease, Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, USA Corresponding author: Anup Solsi, [email protected] Abstract A 30-year-old male presented to the emergency department with dyspnea, fatigue, orthopnea, and paroxysmal nocturnal dyspnea for the past three months. The patient admitted to anabolic steroid use for the past 11 years. Transthoracic echocardiography was significant for severely dilated left ventricle, diffuse hypokinesis, ejection fraction < 15%, and grade II diastolic dysfunction. The patient was diagnosed with decompensated, non-ischemic cardiomyopathy stage C, and New York Heart Classification (NYHA) class III > IV, likely from use of anabolic steroids, after a negative workup for other etiologies. On follow-up after continuation of guideline-directed medical therapy, the patient demonstrated improved heart failure status (NYHA class I > II). Cardiomyopathy is a rare but important adverse effect of anabolic steroids to consider. Categories: Cardiology, Internal Medicine Keywords: dilated cardiomyopathy, anabolic androgenic steroid, systolic heart failure Introduction Since the 1980s, the male sex hormone testosterone and its artificially derived forms, collectively known as anabolic-androgenic steroids (AASs), have been used illicitly by millions of males and females alike as a way to enhance muscle mass.
    [Show full text]
  • Cardiomyopathy ICD-10-CM Clinical Overview
    Cardiomyopathy ICD-10-CM Clinical overview Definition Some cardiomyopathies can be reversible. For example: Cardiomyopathy is a disease of the heart muscle that . Alcoholic cardiomyopathy sometimes can be impairs the function of the heart. reversed with complete cessation of alcohol intake. Takotsubo cardiomyopathy is a reversible, stress- Types induced cardiomyopathy. Cardiomyopathy can be classified as primary or secondary Causes and ischemic or nonischemic. The cause is usually unknown (primary cardiomyopathy), . Primary cardiomyopathy is a noninflammatory disease although contributing factors sometimes can be of the heart muscle, often of obscure or unknown identified. Some of the possible known causes include: cause, that occurs in the absence of other cardiac . Long-term high blood pressure conditions or systemic disease processes. Coronary artery disease . Secondary cardiomyopathy is caused by a known . Heart valve problems medical condition (such as hypertension, valve . Chronic rapid heart rate disease, congenital heart disease or coronary artery . Certain viral infections disease). Some chemotherapy drugs . Pregnancy . Ischemic cardiomyopathy is caused by coronary artery . Excessive, long-term use of alcohol disease and heart attacks, which result in lack of blood . Heart damage, due to a previous heart attack flow to the heart muscle, thereby causing damage to . Metabolic disorders (thyroid disease, diabetes, etc.) the heart muscle. Nutritional deficiencies of essential vitamins and . Nonischemic cardiomyopathy is a type of minerals cardiomyopathy not related to coronary artery disease . Abuse of cocaine or antidepressant medications or poor coronary artery blood flow. There are three . Hemochromatosis – disorder in which iron is not main types of nonischemic cardiomyopathy: properly metabolized, causing build-up in various ‒ Dilated cardiomyopathy (also known as congestive organs, including heart muscle.
    [Show full text]
  • Ischemic Cardiomyopathy
    Patient Information Ischemic Cardiomyopathy BACKGROUND INFORMATION • Cardiomyopathy refers to a condition in which the heart muscle is weakened and not able to maintain normal circulation of your blood. • Ischemic cardiomyopathy is due to blockages in the arteries which supply oxygen to the heart muscle. Over time this leads to damage of the heart muscle, or heart attack, and causes the muscle to weaken. • The most common complication of ischemic cardiomyopathy is congestive heart failure, a condition in which fluid builds up in the lungs and feet causing swelling and difficulty breathing. SYMPTOMS • Chest discomfort, or angina, due to lack of oxygen to the heart muscle • Difficulty breathing • Swelling in your feet or ankles DIAGNOSTIC TESTS • There are several tests used to diagnose ischemic cardiomyopathy. The most common tests include: o Electrocardiogram (EKG) to measure electrical activity of the heart and may help to determine if you’ve suffered a previous heart attack o Echocardiogram or cardiac ultrasound, using sound waves to measure your heart function o Heart catheterization or coronary angiogram. This is done by your doctor inserting a narrow hollow tube into a large artery in your leg or arm and directing the tube up to the heart. Contrast (x-ray) dye is then injected through the tube, allowing your doctor to look for blockages in the vessels supplying blood to the heart. TREATMENT • Medications called diuretics are prescribed to remove extra fluid in your lungs, making it easier for you to breathe • Other medications to help strengthen the heart muscle • Procedures to improve blood flow to the heart muscle, which may include angioplasty or bypass surgery.
    [Show full text]
  • Valvular Heart Disease 2016: Challenges and Future Prospects
    Valvular Heart Disease 2016: Challenges and Future Prospects Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief, JAMA Cardiology No Relationships to Disclose www.acc.org www.americanheart.org The evidence base is limited by an inadequate number of randomized clinical trials www.acc.org www.americanheart.org www.esc.org Hence, virtually all of the recommendations are based on expert consensus (Level C) www.acc.org www.americanheart.org www.esc.org www.acc.org www.americanheart.org www.esc.org Stages of Valvular Heart Disease Stage Definition A Risk of valve disease RHD, BAV, MVP, HF, CVD risk B Mild - moderate asymptomatic disease C Severe valve disease but asymptomatic C1: Normal LV function C2: Depressed LV function D Severe, symptomatic valve disease Mitral regurgitation Degenerative MR: primary valve disease Functional MR: primary myocardial disease Mitral regurgitation Degenerative MR: primary valve disease Functional MR: primary myocardial disease Mitral regurgitation Indications for mitral valve surgery for degenerative MR? Mitral regurgitation Indications for mitral valve surgery for degenerative MR? • Symptomatic patients class I Mitral regurgitation Indications for mitral valve surgery for degenerative MR? • Symptomatic patients class I • Asymptomatic patients • LV systolic dysfunction class I Mitral regurgitation Indications for mitral valve surgery for degenerative MR? • Symptomatic patients class I • Asymptomatic patients
    [Show full text]
  • Mechanisms of Functional Tricuspid Valve Regurgitation in Ischemic Cardiomyopathy
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 2005 Mechanisms of functional tricuspid valve regurgitation in ischemic cardiomyopathy Thomas M. Joudinaud The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Joudinaud, Thomas M., "Mechanisms of functional tricuspid valve regurgitation in ischemic cardiomyopathy" (2005). Graduate Student Theses, Dissertations, & Professional Papers. 9567. https://scholarworks.umt.edu/etd/9567 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. NOTE TO USERS This reproduction is the best copy available. UMI Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Maureen and Mike MANSFIELD LIBRARY The University of Montana Permission is granted by the author to reproduce this material in its entirety, provided that this material is used for scholarly purposes and is properly cited in published works and reports. '*Please check "Yes" or "No" and provide signature Yes, I grant permission K No, I do not grant permission _________ Author's Signature: -------- Date :_______ 03 wA oS Any copying for commercial purposes or financial gain may be undertaken only with the author's explicit consent. 8/98 Reproduced with permission of the copyright owner.
    [Show full text]
  • Endomyocardial Biopsy Plays a Role in Diagnosing Patients With
    Congestive Heart Failure Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy Hossein Ardehali, MD, PhD,a Atif Qasim, MD,b Thomas Cappola, MD,f David Howard,c Ralph Hruban, MD,d Joshua M. Hare, MD,a Kenneth L. Baughman, MD, FACC,a,e and Edward K. Kasper, MD, FACCa Baltimore, Md, Boston, Mass, and Philadelphia, Pa Background The etiology of cardiomyopathy is usually inferred from clinical information and preliminary labora- tory studies. Patients with unexplained cardiomyopathy may be referred for endomyocardial biopsy (EMBx). It is unknown whether pathological information obtained from EMBx is beneficial or alters the diagnosis established clinically. This study was undertaken to evaluate the utility of EMBx in confirming or excluding a clinically suspected diagnosis. Methods We evaluated 845 patients with initially unexplained cardiomyopathy who underwent EMBx between 1982 and 1997 at The Johns Hopkins Hospital. For each patient, an initial clinical diagnosis, an EMBx diagnosis, and a final diagnosis prior to discharge based on all available data were established. Results The final diagnosis differed from the initial clinical diagnosis in 264 (31%) of these patients; EMBx made the diagnosis in 196 (75%) of these cases. Initial diagnoses most frequently altered were myocarditis (34%) and idiopathic cardiomyopathy (25%). Initial diagnoses least likely to be altered were those in which biopsy was used to confirm or grade a previously documented illness, such as hemochromatosis (11%), amyloidosis (18%), or cardiomyopathy second- ary to doxorubicin toxicity (0%). EMBx was more sensitive than clinical diagnosis in detecting myocarditis and amyloi- dosis, and proved to be very specific in detecting ischemic cardiomyopathy, myocarditis, amyloidosis, and hemochroma- tosis.
    [Show full text]
  • ICD-10: Clinical Concepts for Cardiology
    ICD-10 Clinical Concepts for Cardiology ICD-10 Clinical Concepts Series Common Codes Clinical Documentation Tips Clinical Scenarios ICD-10 Clinical Concepts for Cardiology is a feature of Road to 10, a CMS online tool built with physician input. With Road to 10, you can: l Build an ICD-10 action plan customized l Access quick references from CMS and for your practice medical and trade associations l Use interactive case studies to see how l View in-depth webcasts for and by your coding selections compare with your medical professionals peers’ coding To get on the Road to 10 and find out more about ICD-10, visit: cms.gov/ICD10 roadto10.org ICD-10 Compliance Date: October 1, 2015 Official CMS Industry Resources for the ICD-10 Transition www.cms.gov/ICD10 1 Table Of Contents Common Codes • Abnormalities of • Hypertension Heart Rhythm • Nonrheumatic • Atrial Fibrillation and Flutter Valve Disorders • Cardiac Arrhythmias (Other) • Selected Atherosclerosis, • Chest Pain Ischemia, and Infarction • Heart Failure • Syncope and Collapse Clinical Documentation Tips • Acute Myocardial • Atheroclerotic Heart Disease Infraction (AMI) with Angina Pectoris • Hypertension • Cardiomyopathy • Congestive Heart Failure • Heart Valve Disease • Underdosing • Arrythmias/Dysrhythmia Clinical Scenarios • Scenario 1: Hypertension/ • Scenario 4: Subsequent AMI Cardiac Clearance • Scenario: CHF and • Scenario 2: Syncope Pulmonary Embolism Example • Scenario 3: Chest Pain Common Codes ICD-10 Compliance Date: October 1, 2015 Abnormalities of Heart Rhythm (ICD-9-CM 427.81, 427.89, 785.0, 785.1, 785.3) R00.0 Tachycardia, unspecified R00.1 Bradycardia, unspecified R00.2 Palpitations R00.8 Other abnormalities of heart beat R00.9* Unspecified abnormalities of heart beat *Codes with a greater degree of specificity should be considered first.
    [Show full text]
  • A Standardized Definition of Ischemic Cardiomyopathy for Use in Clinical
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 39, No. 2, 2002 © 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(01)01738-7 A Standardized Definition of Ischemic Cardiomyopathy for Use in Clinical Research G. Michael Felker, MD, Linda K. Shaw, MS, Christopher M. O’Connor, MD, FACC Durham, North Carolina OBJECTIVES We sought to evaluate the association between the extent of coronary artery disease (CAD) and survival in patients with symptomatic heart failure (HF) and to create the most prognostically powerful clinical definition of ischemic cardiomyopathy. BACKGROUND An ischemic etiology of HF is known to be a predictor of adverse outcome; however, there is no uniform definition for ischemic cardiomyopathy. METHODS We assessed the clinical history and coronary anatomy of patients with symptomatic HF and ejection fraction Յ40% undergoing diagnostic coronary angiography between 1986 and 1999 (n ϭ 1,921). Five classification schemes were tested to identify the most prognostically powerful method for defining the extent of CAD and to develop the best definition of ischemic cardiomyopathy for prognostic purposes. RESULTS A more extensive CAD was independently associated with shorter survival. When the various classification schemes were compared, a modified number-of-diseased-vessels classification, in which patients with single-vessel disease and no prior history of revascularization or myocardial infarction (MI) were classified as nonischemic, provided the most prognostic power. A definition of ischemic cardiomyopathy that incorporated this definition had more prognostic power than the traditional definition.
    [Show full text]